Medicamentos Parkinson
St. Jude Medical Receives CE Mark Approval For World's Smallest, Longest-Lasting Rechargeable Deep Brain Stimulator For Parkinson's Disease
St. Jude Medical Receives CE Mark Approval For World's Smallest, Longest-Lasting Rechargeable Deep Brain Stimulator For Parkinson's Disease
| Parkinson blog - Medicamentos Parkinson |
Slightly larger than the typical man's watch, the Brio neurostimulator has a thin 10 mm profile and weighs 29 grams (approximately 1 oz). Additionally, the device has the greatest recommended implant depth of any rechargeable DBS device. The thin profile and greater implant depth potentially makes the neurostimulator less noticeable and more comfortable for patients.
"Deep brain stimulation therapy is often the preferred treatment for many Parkinson's disease patients," said Professor Dr. Volker Sturm, chairman of neurosurgery at the University Hospital of Cologne. "For these patients, device size and longevity are important considerations. The small size of the Brio neurostimulator is a real improvement and was a good choice for this patient."
The procedure was performed by Professor Sturm's colleague, Dr. Mohammad Maarouf, at the University Hospital of Cologne.
The Brio DBS system delivers mild electrical pulses to specific targets in the brain, stimulating the structures that are involved in motor control. The system consists of a neurostimulator - a surgically implanted battery-operated device that generates the electrical pulses - and leads which carry the pulses to the brain to influence the irregular nerve signals responsible for the symptoms of Parkinson's disease.
"The Brio neurostimulator is an important addition to our family of deep brain stimulation systems," said Chris Chavez, president of the St. Jude Medical Neuromodulation Division. "We are excited to offer physicians a best-in-class product to help them meet the needs of patients who require a smaller, long-lasting rechargeable system in order to better control the symptoms of this debilitating disease."
| < Prev | Próximo > |
|---|
- 12/09/2011 08:06 - Ven a conocer el equipo de 10 mountains 10 years
- 09/09/2011 21:45 - La suerte es parte de la historia de la medicina
- 04/09/2011 20:02 - Italian Tour Programa completo
- 31/08/2011 08:05 - La DBS sigue siendo eficaz al cabo de 10 años
- 29/08/2011 17:00 - La vida es una guerra perdida, pero hay que ganar las batallas
- 12/01/2010 19:38 - La reducción de la dosis de medicamentos para el Parkinson pueden causar síntomas similares a los de la abstinencia de cocaína
- 15/12/2009 20:27 - La FDA rebaja las restricciones de uso de la rasagilina
- 12/11/2009 23:15 - La dopamina interviene en la toma de decisiones
- 24/10/2009 11:20 - Trastornos del control de impulsos relacionados con la enfermedad de Parkinson
- 24/10/2009 11:17 - La rasagilina puede tener efecto neuroprotector en la enfermedad de Parkinson
- 28/08/2009 13:51 - Riesgo para el juego patológico: imágenes neuronales del proceso de recompensa en uso cronico de agonistas de la dopamina
- 30/07/2009 09:55 - La elección del fármaco dopaminérgico reduce el riesgo de psicosis en enfermos de Parkinson
- 14/05/2009 16:32 - Levodopa y pramipexol: estrategias comparables para la discapacidad del Parkinson
- 24/04/2009 14:15 - La depresión en pacientes con Parkinson responde mejor a la nortriptilina
- 19/12/2008 21:10 - Antidepresivos más antiguos funcionan en pacientes con Parkinson
